Rilpivirine
Fatty Liver Disease
Fundacion SEIMC-GESIDASmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 89/ 100
Competitive context
26 Active assets in the Fatty Liver Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Metformin Leiden University Medical Center | Phase 4 | BBB |
Alpha Tocopherol Yuen Kah Hay | Phase 4 | BB |
Raltegravir Helsinki University Central Hospital | Phase 4 | BB |
Dolutegravir Fundacion SEIMC-GESIDA | Phase 4 | BB |
Pioglitazone Seoul National University Bundang Hospital | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Rilpivirine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →